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Abstract: Despite some limitations such as long-term side effects or the potential presence of intrinsic
or acquired resistance, platinum compounds are key therapeutic components for the treatment of
several solid tumors. To overcome these limitations, maintaining the same efficacy, organometallic
ruthenium(II) compounds have been proposed as a viable alternative to platinum agents as they
have a more favorable toxicity profile and represent an ideal template for both, high-throughput
and rational drug design. To support the preclinical development of bis-phoshino-amine ruthenium
compounds in the treatment of breast cancer, we carried out chemical modifications in the structure
of these derivatives with the aim of designing less toxic and more efficient therapeutic agents. We
report new bis-phoshino-amine ligands and the synthesis of their ruthenium counterparts. The
novel ligands and compounds were fully characterized, water stability analyzed, and their in vitro
cytotoxicity against a panel of tumor cell lines representative of different breast cancer subtypes
was evaluated. The mechanism of action of the lead compound of the series was explored. In vivo
toxicity was also assessed. The results obtained in this article might pave the way for the clinical
development of these compounds in breast cancer therapy.
Keywords: breast cancer; metallodrugs; RAPTA derivatives; phosphino-amine ligands
1. Introduction
Cancer is one of the most devastating diseases in the world and particularly breast
cancer is a leading cause of death in women [1]. Classical treatments for this disease include
chemotherapy, hormonotherapy, and targeted agents such as anti-HER2 treatments [1].
However, it is a global concern that many patients harbor an inherent resistance to these
drugs, and even for those that respond, progression after a specific period of time becomes
frequent [2,3].
Breast cancer can be divided into three different subtypes based on their genomic/
transcriptomic profile, the HER2 enriched, the basal-like, and the luminal breast [4,5]. The
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triple-negative breast cancer subtype mimics the basal-like subgroup and is termed in that
way due to the lack of HER2 and estrogen receptor expression, representing 15% of breast
tumors. It also harbors a more aggressive behavior along with a limited number of efficient
therapeutic options [5]. In this regard, the identification of novel targets with potential for
druggability, the optimization of those that are currently in clinical use, or the development
of new compounds with higher efficacy and a safer toxicity profile, is the main objective.
Platinum-based therapies including carboplatin and cisplatin have been the standard
treatment of care as a chemotherapy backbone, in many solid tumors, such as in triple-
negative and HER2 positive breast cancer [6–8]. Platinum agents are highly cytotoxic
and unspecific, therefore, they can produce severe undesired side effects [9]. In addition,
some tumors express an inherent resistance to these agents and others acquired secondary
resistance after being exposed to these agents for a period of time [2]. In this context, other
metallic compounds with better biological and pharmacological properties are needed.
Rutheniums have emerged as a novel and promising anticancer family of agents [10,11].
Ruthenium-based therapy might overcome platinum resistance, and improve the narrow
therapeutic window of ‘the platinum family of agents’ [12,13]. In addition, ruthenium
compounds have been shown to mediate their biological effect through a combination of
anti-proliferative activity, anti-angiogenic action, and an anti-metastatic property which
can clearly improve the action of current platinum derivatives [14–16].
To date, there have been several ruthenium compounds in clinical trials [17]. NAMI-A
was the first ruthenium agent that eventually reached the clinical stage giving rise to high
expectations for this new class of metal-based anticancer drugs [15,18]. KP1019 and its
sodium salt KP1339 were the following compounds to be evaluated [19]. NAMI-A and KP
compounds were tested in animal models demonstrating activity. Phase II combination
studies of NAMI-A along with gemcitabine against lung cancer reported moderate clinical
activity limiting their further evaluation [20]. Phase I clinical investigation of KP1019 for
patients with advanced solid tumors showed a moderate antitumor activity [21]. The ruthe-
nium compound TLD1433 completed phase I clinical trials for intravesical photodynamic
therapy in patients with a non-muscle invasive bladder tumor and is currently recruiting
patients in a phase II study [22,23].
Organometallic ruthenium compounds such as RAPTA-C [24] and RM175 [25,26] are
in advanced preclinical studies. In this regard, a very high number of new organometallic
ruthenium agents have been reported as potential candidates for clinical translation. Many
examples of the screening of mono-, di-, and poly-nuclear ruthenium compounds with bio-
logically inactive and active auxiliar ligands to give chiral and achiral complexes have been
reported by advanced biological methods to understand their mechanism of action [27–34].
In this context, successful ruthenium complexes have been reported for the treatment of
breast cancer [35]. In this regard, we proposed bis-phoshino-amines as versatile auxiliar
ligands for a direct and simple generation of RAPTA-C derivatives [36]. The cytotoxicity of
the novel ruthenium compounds was studied in a panel of tumoral cells to exploit them
as a promising family of therapeutic agents. In addition, the lead compound of the series
was selected for further evaluation (Figure 1). In a second study, we focused our efforts on
understanding its mode of action, pharmacokinetic and biodistribution parameters and
proposed plausible targets to improve subsequent designs [37].
Herein, a new family of ligands was synthetized and characterized to generate their
ruthenium counterparts. The novel ruthenium agents were evaluated against a panel of
breast tumoral cells representative of the three described breast cancer subtypes and were
also compared to platinum agents. From this work, a new lead complex was obtained, and
its mechanism of action was studied in depth. Finally, in vivo toxicity of the lead compound
and its versatility against other tumor cells overexpressing HER2+ was performed.
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Figure 1. Chemical structure of the lead bis-phosphino-amine compound for breast cancer therapy. 
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breast tumoral cells representative of the three described breast cancer subtypes and were 
also compared to platinum agents. From this work, a new lead complex was obtained, 
and its mechanism of action was studied in depth. Finally, in vivo toxicity of the lead 
compound and its versatility against other tumor cells overexpressing HER2+ was per-
formed. 
2. Materials and Methods 
2.1. General Procedure 
Synthesis reactions were performed using standard Schlenk and glove-box tech-
niques under an atmosphere of dry nitrogen. CH2Cl2 and hexane were pre-dried over 
CaCl2 and sodium wire, respectively, and distilled under nitrogen from sodium-potas-
sium alloy (hexane), and CaCl2 (CH2Cl2). CDCl3, DMSO-d6, and D2O were stored over ac-
tivated 4 Å  molecular sieves and degassed by several freeze-thaw cycles. All NMR exper-
iments were conducted in deuterated solvents at 297 K in a Varian FT-400 spectrometer 
(VARIAN Inc., Palo Alto, California, USA) equipped with a 4 nucleus ASW PFG 
1H/19F/13C/{15N-31P}. The 1H π/2 pulse length was adjusted for each sample. 1H- and 13C{1H}-
NMR chemical shifts (δ) are given in ppm relative to TMS. 31P{1H}-NMR chemical shifts 
are given in ppm relative to H3PO4 (85%). Coupling constants (J) are documented in Hz. 
The solvent signals were used as references and chemical shifts converted to the TMS 
scale. IR experiments were conducted on an FT/IR-4000 Series Jasco Instruments (Jasco 
Analytics, Madrid, Spain). The UV-Vis absorption spectra were recorded at room temper-
ature using a Cary 100 spectrophotometer (Agilent, Madrid, Spain) using a slit width of 
0.4 nm and a scan rate of 600 nm/min. Elemental Analysis was performed at the Unidad 
de Análisis Químico Elemental, University complutense, Madrid (Spain) using an Ele-
mentary Chemical Analyzer LECO CHNS-932. Mass spectroscopy was performed at the 
Unidad de Espectrometría de Masas, University complutense, Madrid (Spain) using a 
MAXXIS II Bruker spectrometer. 
2.2. Synthesis and Characterization of Ligands L1-L10 
To a solution of chlorodiphenylphosphine (0.54 mL, 2.92 mmol) in toluene (15 mL) 
at 0 °C were added dropwise triethylamine (0.45 mL, 3.22 mmol) and the corresponding 
amine (1.45 mmol). After a 30 min stirring time, the ice bath was removed, and the stirring 
continued. Monitoring by NMR showed all starting materials to have been consumed 
within 5 h; at this point, the solution was filtered to remove the Et3NHCl formed. On re-
moving all volatiles under reduced pressure, the resultant white solid was repeatedly 
washed with degassed MeCN until no Ph2PP(O)Ph2 impurity could be detected by 31P{1H}-
NMR. 
N-tert-butyl-N-(diphenylphosphanyl)-1,1-diphenylphosphanamine (L1): After extracting 
in toluene, L1 was recovered as a white solid with a yield of 86%. 1H NMR (400 MHz, 
CDCl3) δ 7.88–7.17 (m, 20 H, Ar), 1.43 (s, J = 7.9 Hz, 9 H, CH3). 13C{1H}-NMR (101 MHz, 
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2. Materials and Methods
2.1. General Procedure
Synthesis reactions w re performed using standard Schlenk and glove-box techniques
under an at osphere of dry nitrogen. CH2Cl2 nd hexane were pre-dried over CaCl2
and sodi m wire, res ectively, and distilled under nitrogen from sodium-potassium alloy
(hexane), and CaCl2 (CH2Cl2). CDCl3, DMSO-d6, and D2O were stored over activated 4 Å
molecular sieves and degassed by several freeze-thaw cycles. All NMR experiments were
conducted in deuterated solvents at 297 K in a Varian FT-400 spectrometer (VARIAN Inc.,
Palo Alto, California, USA) equipped with a 4 nucleus ASW PFG 1H/19F/13C/{15N-31P}.
The 1H π/2 pulse length was adjusted for each sample. 1H- and 13C{1H}-NMR chemical
shifts (δ) are given in ppm relative to TMS. 31P{1H}-NMR chemical shifts are given in
ppm relative to H3PO4 (85%). Coupling constants (J) are documented in Hz. The solvent
signals were used as references and chemical shifts converted to the TMS scale. IR experi-
ments were conducted on an FT/IR-4000 Series Jasco Instruments (Jasco Analytics, Madrid,
Spain). The UV-Vis absorption spectra were recorded at room temperature using a Cary
100 spectrophotometer (Agilent, Madrid, Spain) using a slit width of 0.4 nm and a scan rate
of 600 nm/min. Elemental Analysis was performed at the Unidad de Análisis Químico Ele-
mental, University complutense, Madrid (Spain) using an Elementary Chemical Analyzer
LECO CHNS-932. Mass spectroscopy was performed at the Unidad de Espectrometría de
Masas, University complutense, Madrid (Spain) using a MAXXIS II Bruker spectrometer.
2.2. Synthesis and Chara terization of Ligands L1–L10
To a solution of chlorodiphenylphosphine (0.54 mL, 2.92 mmol) in toluene (15 mL)
at 0 ◦C were added dropwise triethylamine (0.45 mL, 3.22 mmol) and the corresponding
amine (1.45 mmol). After a 30 min stirring time, the ice bath was removed, and the stirring
continued. Monitoring by NMR showed all starting materials to have been consumed
within 5 h; at this point, the solution was filtered to remove the Et3NHCl formed. On
removing all volatiles under reduced pressure, the resultant white solid was repeatedly
washed with degassed MeCN ntil no Ph2PP(O)Ph2 impurity could be detected by 31P{1H}-
NMR.
N-tert-butyl-N-(diphenylphosphanyl)-1,1-diphenylphosphanamine (L1): After extracting
in toluene, L1 was recovered as a white solid with a yield of 86%. 1H NMR (400 MHz,
CDCl3) δ 7.88–7.17 (m, 20 H, Ar), 1.43 (s, J = 7.9 Hz, 9 H, CH3). 13C{1H}-NMR (101 MHz,
CDCl3) δ 140.74 (4 C, Ar quaternary (PPh2)), 132.81 (8 C, o-Ar CH (PPh2)), 128.23 (8 C,
m-Ar CH(PPh2)), 127.91 (4 C, p-Ar CH(PPh2)), 63.8 (1 C, C–(CH3)3), 32.75 (3 C, CH3). 31P
R (162 MHz, CDCl3) δ 21.39. UV-vis: maximum absorbance at 288 nm. IR: 2961 cm−1
(C–H sp3 stretching), 1476–1431 cm−1 (two bands C=C aromatic stretching), 1174 cm−1
(C–N stretching), 1087 cm−1 (C–P stretching). Elemental analysis calcd (%) for C28H29NP2:
C, 76.17; H, 6.62; N, 3.17; P, 14.03; found: C, 76.12; H, 6.52; N, 3.31.
N-(diphenylphosphanyl)-1,1-diphenyl-N-propylphosphanamine (L2): After extracting in
toluene, L3 was recovered as a white solid with a yield of 84%. 1H NMR (400 MHz, CDCl3) δ
7.40–7.33 (m, 8H, o-Ar), 7.30–7.24 (m, 12H, m- and p-Ar), 3.20–3.09 (m, 2H, -CH2-CH2-CH3),
1.11–0.95 (m, 2H, –CH2–CH2–CH3), 0.45 (t, J = 7.3 Hz, 3H, –CH2–CH2–CH3). 13C{1H}-NMR
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(101 MHz, CDCl3) δ 139.66 (4 C, Ar quaternary (PPh2)), 132.65 (8 C, o-Ar CH (PPh2)),
128.65 (6 C, m- and p-Ar CH (PPh2)), 127.95 (6 C, m- and p-Ar CH (PPh2)), 54.65 (2 C, –CH2–
CH2–CH3), 24.60 (2 C, –CH2–CH2–CH3), 10.94 (3 C, –CH2–CH2–CH3). UV-vis: maximum
absorbance at 284 nm. IR: 2957 cm−1 (C–H sp3 stretching), 1478–1433 cm−1 (two bands C=C
aromatic stretching), 1090 cm−1 (C–P stretching), 1057 cm−1 (C–N stretching). Elemental
analysis calcd (%) for C27H27NP2: C, 75.86; H, 6.37; N, 3.28; found: C, 75.69; H, 6.52; N,
3.39.
N-cyclohexyl-N-(diphenylphosphanyl)-1,1-diphenylphosphanamine (L3): After extracting
in toluene, L3 was recovered as a white solid with a yield of 82%. 1H NMR (400 MHz,
CDCl3) δ 7.24 (m, 20H, Ar), 3.29–3.11 (m, 1H, cyclohexyl CH), 1.93–1.74 (m, 2H, cyclohexyl
CH2), 1.64–1.30 (m, 4H, cyclohexyl CH2), 1.12–0.89 (m, 4H, cyclohexyl CH2). 13C{1H}-NMR
(101 MHz, CDCl3) δ 140.00 (4C, Ar quaternary (PPh2)), 132.64 (8C, o-Ar CH (PPh2)), 128.48
(8C, m-Ar CH (PPh2)), 127.96 (4 C, p-Ar CH (PPh2)), 60.33 (1 C, cyclohexyl CH), 34.89
(1 C, cyclohexyl CH2), 26.12 (2C, cyclohexyl CH2), 25.47 (2C, cyclohexyl CH2). 31P NMR
(162 MHz, CDCl3) δ 55.78. UV-vis: maximum absorbance at 276 nm. IR: 2927 cm−1 (C–H
sp3 stretching), 1449–1433 cm−1 (two bands C=C aromatic stretching), 1091 cm−1 (C–P
stretching), 1056 cm−1 (C–N stretching). Elemental analysis calcd (%) for C30H31NP2: C,
77.07; H, 6.68; N, 3.00; found: C, 76.84; H, 6.88; N, 3.31.
N-(diphenylphosphanyl)-N,1,1-triphenylphosphanamine (L4): After extracting in toluene,
L4 was recovered as a white solid with a yield of 91%. 1H NMR (400 MHz, CDCl3) δ
7.40–7.21 (m, 20H), 6.99–6.88 (m, 3H), 6.64 (d, J = 6.2 Hz, 2H). 13C{1H}-NMR (101 MHz,
CDCl3) δ 159.32 (2C, o-Ar quaternary (o-Ph)), 158.02 (1C, Ar quaternary (o-Ph)), 140.28 (4C,
Ar quaternary (PPh2)), 132.32 (8C, o-Ar CH (PPh2)), 128.03 (2C, m-Ar (o-Ph)), 127.65 (8C,
m-Ar CH (PPh2)), 126.92 (4C, p-Ar CH (PPh2)), 122.03 (2C, o-Ar (o-Ph)), 117.22 (1C, p-Ar
(o-Ph)). 31P NMR (162 MHz, CDCl3) δ 68.46. UV-vis: maximum absorbance at 280 nm. IR:
3057 cm−1 (C–H sp2 stretching), 1488–1431 cm−1 (two bands C=C aromatic stretching),
1172 cm−1 (C–N stretching), 1091 cm−1 (C–P stretching). Elemental analysis calcd (%) for
C30H25NP2: C, 78.08; H, 5.46; N, 3.04; found: C, 78.12; H, 5.54; N, 3.30.
N-(diphenylphosphanyl)-N-(2-fluorophenyl)-1,1-diphenylphosphanamine (L5): After extract-
ing in toluene, L5 was recovered as a white solid with a yield of 80%. 1H NMR (400 MHz,
CDCl3) δ 7.40–7.18 (m, 20 H, Ar (PPh2)), 7.04–6.96 (m, 1H, o-Ar (o-FPh)), 6.87–6.77 (m, 1H,
p-Ar (o-FPh)), 6.76–6.62 (m, 2H, m-Ar (o-FPh)). 13C{1H}-NMR (101 MHz, CDCl3) δ 160.47
(1C, o-Ar quaternary (o-FPh)), 158.02 (1C, Ar quaternary (o-FPh)), 139.18 (4C, Ar quater-
nary (PPh2)), 133.39 (8C, o-Ar CH (PPh2)), 131.43 (1C, m-Ar (o-FPh)), 129.05 (8C, m-Ar CH
(PPh2)), 127.97 (4C, p-Ar CH (PPh2)), 127.08 (1C, o-Ar (o-FPh)), 123.59 (1C, m-Ar (o-FPh)),
116.21 (1C, p-Ar (o-FPh)). UV-vis: maximum absorbance at 280 nm. IR: 3057 cm−1 (C–H
sp2 stretching), 1479–1432 cm−1 (two bands C=C aromatic stretching), 1245 cm−1 (C–F
stretching), 1181 cm−1 (C–N stretching), 1089 cm−1 (C–P stretching). Elemental analysis
calcd (%) for C30H24FNP2: C, 75.15; H, 5.05; N, 2.92; found: C, 74.92; H, 5.11; N, 3.18.
N-(diphenylphosphanyl)-N-(4-fluorophenyl)-1,1-diphenylphosphanamine (L6): After extract-
ing in toluene, L6 was recovered as a white solid with a yield of 86%. 1H NMR (400 MHz,
CDCl3) δ 7.38–7.19 (m, 20H, Ar), 6.58 (t, J = 8.7 Hz, 2H, m-Ar (p-FPh)), 6.48 (dd, J = 8.9, 5.1
Hz, 2H, o-Ar (p-FPh)). 13C{1H}-NMR (101 MHz, CDCl3) δ 161.44 (1C, p-Ar quaternary(p-
FPh)), 159.01 (1C, Ar quaternary (p-FPh)), 138.93 (4C, Ar quaternary (PPh2)), 133.20 (8C,
o-Ar CH (PPh2)), 130.67 (2C, m-Ar CH (p-FPh)), 129.11 (8C, m-Ar CH (PPh2)), 128.00 (4C,
p-Ar CH (PPh2)), 114.79 (2C, o-Ar CH (p-FPh)). UV-vis: maximum absorbance at 278 nm.
IR: 3056 cm−1 (C-H sp2 stretching), 1496–1430 cm−1 (two bands C=C aromatic stretching),
1202 cm−1 (C–F stretching), 1151 cm−1 (C–N stretching), 1091 cm−1 (C–P stretching). Ele-
mental analysis calcd (%) for C30H24FNP2: C, 75.15; H, 5.05; N, 2.92; found: C, 75.33; H,
5.27; N, 3.11.
N-(3-bromophenyl)-N-(diphenylphosphanyl)-1,1-diphenylphosphanamine (L7): After extract-
ing in toluene, L7 was recovered as a white solid with a yield of 92%. 1H NMR (400 MHz,
CDCl3) δ 7.40–7.19 (m, 20H, Ar (PPh2)), 7.08 (d, J = 8.2 Hz, 1H, o-Ar (m-BrPh)), 6.81 (t,
J = 8.0 Hz, 1H, m-Ar (m-BrPh)), 6.68 (s, 1H, o’-Ar (m-BrPh)), 6.62 (d, J = 8.0 Hz, 1H, p-Ar (m-
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BrPh)). 13C{1H}-NMR (101 MHz, CDCl3) δ 148.66 (4C, Ar quaternary (m-BrPh)), 138.57 (2C,
m’-Ar quaternary (m-BrPh) and Ar quaternary (PPh2)), 133.13 (8C, o-Ar CH (PPh2)), 131.95
(1C, p-Ar (m-BrPh)), 129.20 (8C, m-Ar CH (PPh2)), 128.04 (4C, p-Ar CH (PPh2)), 127.43 (2C,
o-Ar (m-BrPh)), 121.36 (1C, m-Ar (m-BrPh)). 31P NMR (162 MHz, CDCl3) δ 68.65. UV-vis:
maximum absorbance at 282 nm. IR: 3072 cm−1 (C–H sp2 stretching), 1465–1432 cm−1 (two
bands C=C aromatic stretching), 1203 cm−1 (C–N stretching), 1091 cm−1 (C–P stretching),
690 cm−1 (C–Br stretching). Elemental analysis calcd (%) for C30H24BrNP2: C, 66.68; H,
4.48; N, 2.59; found: C, 66.92; H, 4.53; N, 2.75.
N-(4-chlorophenyl)-N-(diphenylphosphanyl)-1,1-diphenylphosphanamine (L8): After extract-
ing in toluene, L8 was recovered as a white solid with a yield of 90%. 1H NMR (400 MHz,
CDCl3) δ 7.36–7.19 (m, 20H, Ar (PPh2)),), 6.85 (d, J = 8.7 Hz, 2H, m-Ar CH (p-ClPh)), 6.48 (d,
J = 8.8 Hz, 2H, o-Ar CH(p-ClPh)). 13C{1H}-NMR (101 MHz, CDCl3) δ 145.62 (1C, Ar quater-
nary (p-ClPh)), 138.72 (5C, p-Ar quaternary(p-ClPh) and Ar quaternary (PPh2)), 133.15 (8C,
o-Ar CH (PPh2)), 130.22 (2C, m-Ar CH (p-ClPh)), 129.15 (8C, m-Ar CH (PPh2)), 128.17 (2C,
o-Ar CH (p-ClPh)), 128.06 (4C, p-Ar CH (PPh2)). 31P NMR (162 MHz, cdcl3) δ 69.64. UV-vis:
maximum absorbance at 282 nm. IR: 3036 cm−1 (C–H sp2 stretching), 1477–1431 cm−1 (two
bands C=C aromatic stretching), 1211 cm−1 (C–N stretching), 1092 cm−1 (C–P stretching),
901 cm−1 (C–Cl stretching). Elemental analysis calcd (%) for C30H24ClNP2: C, 72.66; H,
4.88; N, 2.82; found: C, 72.45; H, 4.46; N, 2.62.
N,N-bis(diphenylphosphanyl)quinolin-6-amine (L9): After extracting in toluene, L9 was
recovered as a yellow solid with a yield of 78%. 1H NMR (400 MHz, CDCl3) δ 8.73 (dd,
J = 4.2, 1.7 Hz, 1H, Ar CH8 (quinoline)), 7.67 (t, J = 9.6 Hz, 2H, Ar CH9 and Ar CH10
(quinoline)), 7.41–7.32 (m, 8H, o-Ar (PPh2)), 7.33–7.23 (m, 12H, m-Ar and p-Ar (PPh2)), 7.20
(dd, J = 8.3, 4.3 Hz, 1H, Ar CH3 (quinoline)), 7.10 (d, J = 9.0 Hz, 1H, Ar CH2 (quinoline)),
6.93 (s, 1H, Ar CH6 (quinoline)). 13C{1H}-NMR (101 MHz, CDCl3) δ 149.65 (1 C, C8
(quinoline)), 145.95 (1 C, C1 (quinoline)), 145.66 (1 C, C4 (quinoline)), 138.75 (4 C, Ar
quaternary (PPh2)), 135.66 (1 C, C10 (quinoline)), 133.17 (8 C, o-Ar CH (PPh2)), 131.77 (1
C, C5 (quinoline)), 129.19 (8 C, m-Ar CH (PPh2)), 129.12 (1 C, C2 (quinoline)), 128.10 (1 C,
C3 (quinoline)), 127.94 (4 C, p-Ar CH (PPh2)), 125.90 (1 C, C6 (quinoline)), 120.89 (1 C, C9
(quinoline)). 31P NMR (162 MHz, cdcl3) δ 68.73. UV-vis: maximum absorbance at 282 nm.
IR: 3047 cm−1 (C–H sp2 stretching), 1492–1431 cm−1 (two bands C=C aromatic stretching),
1210 cm−1 (C–N stretching), 1094 cm−1 (C–P stretching). Elemental analysis calcd (%) for
C33H26N2P: C, 77.33; H, 5.11; N, 5.47; found: C, 77.22; H, 5.32; N, 5.81.
(E)-N-(diphenylphosphanyl)-1,1-diphenyl-N-(4-(phenyldiazenyl)phenyl)phosphanamine (L10):
After extracting in toluene, L10 was recovered as a yellow solid with a yield of 79%. 1H
NMR (400 MHz, CDCl3) δ 7.82 (d, J = 6.9 Hz, 2H, H3 and H5 (azobenzene)), 7.53 (d,
J = 8.8 Hz, 2H, H10 and H14 (azobenzene)), 7.45 (d, J = 7.5 Hz, 2H, H11 and H13 (azoben-
zene)), 7.42–7.38 (m, 8H, o-Ar (PPh2)), 7.34 (t, J = 1.5 Hz, 1H, H12 (azobenzene)), 7.33–7.23
(m, 12H, m-Ar and p-Ar (azobenzene)), 6.81 (d, J = 8.8 Hz, 2H, H2 and H6 (azobenzene)).
13C{1H}-NMR (101 MHz, CDCl3) δ 152.59 (1 C, C9 (azobenzene)), 150.47 (1 C, C1 (azoben-
zene)), 149.38 (1 C, C4 (azobenzene)), 138.55 (4 C, Ar quaternary (PPh2)), 133.15 (8 C, o-Ar
CH (PPh2)), 130.72 (2 C, C3 and C5 (azobenzene)), 129.19 (8 C, m-Ar CH (PPh2)), 129.02
(2 C, C11 and C13 (azobenzene)), 128.83 (2 C, C10 and C14 (azobenzene)), 128.12 (4 C,
p-Ar CH (PPh2)), 122.82 (1 C, C2 (azobenzene)), 122.66 (1 C, C6 (azobenzene)). UV-vis:
maximum absorbance at 358 nm. IR: 3047 cm−1 (C–H sp2 stretching), 1492 cm−1 (N=N
stretching), 1478–1434 cm−1 (two bands C=C aromatic stretching), 1214 cm−1 (C–N stretch-
ing), 1091 cm−1 (C–P stretching). Elemental analysis calcd (%) for C36H29N3P2: C, 76.45; H,
5.17; N, 7.43; found: C, 76.71; H, 5.32; N, 7.75.
2.3. Synthesis and Characterization of Ruthenium Compounds Ru1–Ru10
To a mixture of ligand (0.07 mmol), [RuCl2(p-cym)]2 (0.023 g, 0.037 mmol) and NaBF4
(0.010 g, 0.091 mmol) was added methanol (3 mL) and the mixture was allowed to stir for
4 h at room temperature. After this time, a white precipitate appeared. The complexes
were isolated as orange solids after filtration.
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[RuCl(p-cym)({Ph2P}2N{C4H9})][BF4] (Ru1). Yield: 46.32 mg, 0.064 mmol, 85%. 1H
NMR (400 MHz, CDCl3) δ 8.23–8.10 (d, J = 6.6 Hz, 8 H, o-Ar), 7.85 (t, J = 7.4 Hz, 4 H, p-Ar),
7.67 (t, J = 7.3 Hz, 8 H, m-Ar), 5.88 (d, J = 6.4 Hz, 2 H, cym), 5.85 (d, J = 6.5 Hz, 2 H, cym),
2.60–2.49 (m, 1 H, CH3–CH–CH3), 1.95 (d, J = 5.9 Hz, 3 H, CH3), 0.96 (d, J = 6.9 Hz, 6 H,
CH3–CH–CH3), 0.71 (s, 9 H, CH3). 13C{1H}-NMR (101 MHz, CDCl3) δ 135.36 (8 C, o-Ar CH
(PPh2), 132.64 (8 C, m-Ar CH (PPh2), 130.22 (4 C, p-Ar CH (PPh2), 98.50 (4 C, cym), 31.82 (1
C, CH–CH3)2), 31.18 (3 C, CH3), 22.81 (2 C, CH3–CH), 18.62 (1 C, CH3). Quaternary carbons
were not found. 31P NMR (162 MHz, CDCl3) δ 79.91. UV-vis: maximum absorbance at
280 nm. IR: 2963 cm−1 (C–H sp3 stretching), 1474–1436 cm−1 (two bands C=C aromatic
stretching), 1090 cm−1 (C–N stretching), 1053 cm−1 (C–P stretching), 701 cm−1 (Ru–Cl
stretching). Elemental analysis calcd (%) for C38H43BClF4NP2Ru: C, 57.12; H, 5.42; N, 1.75;
found: C, 57.93; H, 5.15; N, 1.97. MS (ESI) m/z for [C38H43ClNP2Ru+]: 712.16 (100%).
[RuCl(p-cym)({Ph2P}2N{C3H7})][BF4] (Ru2). Yield: 49.41 mg, 0.070 mmol, 93%. 1H
NMR (400 MHz, CDCl3) δ 7.54 (dd, J = 61.7, 29.3 Hz, 20 H, Ar), 6.05 (s, 2 H, cym), 5.79 (s,
2 H, cym), 2.75 (t, J = 4.3 Hz, 2 H, CH2–CH2–CH3), 2.55 (s, 1 H, CH3–CH–CH3), 1.79 (s, 3
H, CH3), 1.10–0.94 (m, 2 H, CH2–CH2–CH3), 1.06 (d, J = 6.8 Hz, 6 H, CH3–CH–CH3), 0.40
(s, 3 H, CH2–CH2–CH3). 13C{1H}-NMR (101 MHz, CDCl3) δ 133.55 (4 C, Ar quaternary
(PPh2)), 132.65 (8 C, m-Ar CH (PPh2)), 130.07 (8 C, o-Ar CH (PPh2)), 127.95 (4 C, p-Ar
CH (PPh2)), 117.87 (1 C, cym quaternay), 111.04 (1 C, cym quaternary) 95.95 (2 C, cym),
90.19 (2 C, cym), 52.26 (1 C, CH2–CH2–CH3), 31.77 (1 C, CH–CH3)2), 23.46 (1 C, CH2–
CH2–CH3), 22.79 (2 C, CH3–CH), 18.85 (1 C, CH3), 11.15 (1 C, CH2–CH2–CH3). 31P NMR
(162 MHz, CDCl3) δ 76.56. UV-vis: maximum absorbance at 276 nm. IR: 2966 cm−1 (C–H
sp3 stretching), 1477–1435 cm−1 (two bands C=C aromatic stretching), 1091 cm−1 (C–N
stretching), 1050 cm−1 (C–P stretching), 695 cm−1 (Ru–Cl stretching). Elemental analysis
calcd (%) for C37H41BClF4NP2Ru: C, 56.61; H, 5.26; N, 1.78; found: C, 56.68; H, 5.48; N,
1.87. MS (ESI) m/z for [C37H41ClNP2Ru+]: 698.14 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H11})][BF4] (Ru3). Yield: 53.11 mg, 0.072 mmol, 92%. 1H
NMR (400 MHz, CDCl3) δ 7.89–7.42 (m, 20 H, Ar), 5.99 (t, J = 6.8 Hz, 2 H, cym), 5.95 (d, J =
6.2 Hz, 2 H, cym), 2.66–2.53 (m, 1 H, CH3–CH–CH3), 2.03 (s, 3 H, CH3), 1.23 (t, J = 16.6 Hz,
4 H, cyclohexyl CH2), 1.11 (d, J = 11.5 Hz, 2 H, cyclohexyl CH2), 1.02 (d, J = 6.9 Hz, 6 H,
CH3–CH–CH3), 0.63 (t, J = 13.1 Hz, 1 H, cyclohexyl CH), 0.55–0.40 (m, 4 H, cyclohexyl
CH2). 13C{1H}-NMR (101 MHz, CDCl3) δ 134.33 (8 C, o-Ar CH (PPh2)), 133.71 (4 C, Ar
quaternay (PPh2)) 132.36 (8 C, m-Ar CH (PPh2)), 130.03 (4 C, p-Ar CH (PPh2)), 116.76
(1 C, cym quaternary), 112.54 (1 C, cym quaternary), 96.29 (2 C, cym), 89.63 (2 C, cym),
33.19–32.77 (2 C, cyclohexyl CH2), 31.73 (1 C, CH–CH3)2), 25.95 (2 C, cyclohexyl CH2),
24.51 (2 C, cyclohexyl CH2 and cyclohexyl CH), 22.83 (2 C, CH3–CH), 19.01 (1 C, CH3). 31P
NMR (162 MHz, CDCl3) δ 75.97. UV-vis: maximum absorbance at 276 nm. IR: 2941 cm−1
(C–H sp3 stretching), 1478–1434 cm−1 (two bands C=C aromatic stretching), 1075 cm−1
(C–N stretching), 1046 cm−1 (C–P stretching), 699 cm−1 (Ru–Cl stretching). Elemental
analysis calcd (%) for C40H45BClF4NP2Ru: C, 58.23; H, 5.50; N, 1.70; found: C, 58.42; H,
5.39; N, 1.61. MS (ESI) m/z for [C40H45ClNP2Ru+]: 731.18 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H5})][BF4] (Ru4). Yield: 51.31 mg, 0.070 mmol, 92%.1H NMR
(400 MHz, CDC3) δ 7.68–7.56 (m, 8 H, o-Ar (PPh2)), 7.54–7.43 (m, 8 H, m-Ar (PPh2)), 7.35
(t, J = 7.6 Hz, 4 H, p-Ar (PPh2)), 7.04 (t, J = 7.3 Hz, 1 H, p-phenyl), 6.96 (t, J = 7.7 Hz, 2
H, m-phenyl), 6.54 (d, 2 H, o-phenyl), 6.06 (d, J = 6.3 Hz, 2 H, cym), 5.83 (d, J = 6.3 Hz, 2
H, cym), 2.57–2.47 (m, J = 13.8, 6.8 Hz, 1 H, CH3–CH–CH3), 1.68 (s, 3 H, CH3), 1.09 (d,
J = 6.9 Hz, 6 H, CH3–CH–CH3). 13C{1H}-NMR (101 MHz, CDCl3) δ 139.66 (1 C, phenyl
quaternary), 133.41 (8 C, o-Ar CH (PPh2)), 132.79 (4 C, Ar quaternary (PPh2), 129.82 (8 C,
m-Ar CH (PPh2)), 128.97 (2 C, phenyl m-Ar CH), 127.83 (4 C, p-Ar CH (PPh2)), 126.73 (1 C,
phenyl p-Ar CH), 126.51 (2 C, phenyl o-Ar CH), 120.58 (1 C, cym quaternary), 109.01 (1 C,
cym quaternary), 94.69–93.57 (2 C, cym), 92.19 (2 C, cym), 31.44 (1 C, CH-(CH3)2), 22.49
(2 C, CH3-CH), 18.00 (1 C, CH3). 31P NMR (162 MHz, CDCl3) δ 79.01. UV-vis: maximum
absorbance at 276 nm. IR: 2962 cm−1 (C-H sp3 stretching), 1482–1435 cm−1 (two bands
C=C aromatic stretching), 1089 cm−1 (C–N stretching), 1031 cm−1 (C–P stretching), 691
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cm−1 (Ru–Cl stretching). Elemental analysis calcd (%) for C40H39BClF4NP2Ru: C, 58.66;
H, 4.80; N, 1.71; found: C, 58.79; H, 4.48; N, 1.97. MS (ESI) m/z for [C40H38ClFNP2Ru+]:
731.18 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H4F})][BF4] (Ru5). Yield: 50.19 mg, 0.067 mmol, 89%. 1H
NMR (400 MHz, CDCl3) δ 7.57 (s, 8 H, o-Ar (PPh2)), 7.50–7.39 (m, 8 H, m-Ar (PPh2)), 7.29
(t, J = 7.5 Hz, 4 H, p-Ar (PPh2)), 7.14 (t, J = 10.2 Hz, 1 H, p-Ar (o-FPh)), 6.97 (t, J = 9.1 Hz,
1 H, m’-Ar (o-FPh)), 6.62 (t, J = 7.6 Hz, 1 H, m-Ar (o-FPh)), 6.17 (d, J = 6.2 Hz, 2 H, cym),
6.08 (t, J = 7.6 Hz, 1 H, o-Ar (o-FPh)), 5.90 (d, J = 6.0 Hz, 2 H, cym), 2.60–2.47 (m, 1 H,
CH3-CH-CH3), 1.69 (s, 3 H, CH3), 1.11 (d, J = 6.9 Hz, 6 H, CH3-CH-CH3). 13C{1H}-NMR
(101 MHz, CDCl3) δ 134.15 (1 C, o’-Ar quaternary (o-FPh), 134.00 (1 C, o-Ar (o-FPh)), 132.94
(8 C, m-Ar CH (PPh2)), 131.94 (4 C, Ar quaternary (PPh2)), 130.53 (1 C, p-Ar (o-FPh)), 129.43
(8 C, o-Ar CH (PPh2)), 128.12 (1 C, Ar quaternary (o-FPh)), 127.69 (4 C, p-Ar CH (PPh2)),
124.25 (1 C, m-Ar (o-FPh)), 120.59 (1 C, cym quaternary), 116.96 (1 C, m’-Ar (o-FPh)), 108.09
(1 C, cym quaternary), 93.89 (2 C, cym), 92.57 (2 C, cym), 31.31 (1 C, CH–(CH3)2), 22.47
(2 C, CH3–CH), 17.99–16.94 (1 C, CH3). 31P NMR (162 MHz, CDCl3) δ 84.21. UV-vis:
maximum absorbance at 272 nm. IR: 3065 cm−1 (C–H sp2 stretching), 2968 cm−1 (C–H
sp3 stretching), 1485–1435 cm−1 (two bands C=C aromatic stretching), 1257 cm−1 (C–F
stretching), 1097 cm−1 (C–N stretching), 1050 cm−1 (C–P stretching), 691 cm−1 (Ru–Cl
stretching). Elemental analysis calcd (%) for C40H38BClF5NP2Ru: C, 57.40; H, 4.58; N, 1.67;
found: C, 57.72; H, 4.32; N, 1.83. MS (ESI) m/z for [C40H38ClFNP2Ru+]: 750.12 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H4F})][BF4] (Ru6). Yield: 51.40 mg, 0.068 mmol, 90%. 1H
NMR (400 MHz, CDCl3) δ 7.67–7.32 (m, 20 H, Ar (PPh2)), 6.71–6.63 (t, 2 H, o-Ar (p-FPh)),
6.52–6.45 (m, 2 H, m-Ar (p-FPh)), 6.15 (d, J = 6.3 Hz, 2 H, cym), 5.90 (d, J = 6.2 Hz, 2 H, cym),
2.60–2.50 (m, 1 H, CH3–CH–CH3), 1.74 (s, 3 H, CH3), 1.09 (d, J = 6.9 Hz, 6 H, CH3-CH-CH3).
13C{1H}-NMR (101 MHz, CDCl3) δ 133.62 (1 C, p-Ar quaternary (p-FPh)), 133.38 (4 C, Ar
quaternary (PPh2)), 133.22 (8 C, Ar CH (PPh2)), 131.94 (1 C, Ar quaternary (p-FPh)), 130.11
(2 C, m-Ar CH (p-FPh)), 129.83 (8 C, Ar CH (PPh2)), 127.81 (4 C, Ar CH (PPh2)), 119.96
(1 C, cym quaternary), 115.83 (2 C, o-Ar CH (p-FPh)), 110.03 (1 C, cym quaternary), 94.94
(2 C, cym), 91.74 (2 C, cym), 31.59 (1 C, CH–(CH3)2), 22.61 (2 C, CH3–CH), 18.26 (1 C,
CH3). 31P NMR (162 MHz, CDCl3) δ 81.02. UV-vis: maximum absorbance at 274 nm. IR:
3071 cm−1 (C–H sp2 stretching), 2965 cm−1 (C–H sp3 stretching), 1503–1434 cm−1 (two
bands C=C aromatic stretching), 1212 cm−1 (C–F stretching), 1093 cm−1 (C–N stretching),
1050 cm−1 (C–P stretching), 691 cm−1 (Ru–Cl stretching). Elemental analysis calcd (%) for
C40H38BClF5NP2Ru: C, 57.40; H, 4.58; N, 1.67; found: C, 57.51; H, 4.61; N, 1.88. MS (ESI)
m/z for [C40H38BrClNP2Ru+]: 810.04 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H4Br})][BF4] (Ru7). Yield: 56.04 mg, 0.069 mmol, 92%. 1H
NMR (400 MHz, CDCl3) δ 7.74–7.33 (m, J = 51.1, 40.4, 17.9 Hz, 22 H, Ar (PPh2), o-Ar CH
(m-BrPh) and m-Ar CH (m-BrPh)), 6.93 (d, J = 8.7 Hz, 1 H, p-Ar CH (m-BrPh)), 6.44 (d, J =
8.7 Hz, 1 H, o-Ar CH (m-BrPh)), 6.12 (d, 2 H, cym), 5.91 (d, 2 H, cym), 2.59–2.49 (m, 1 H,
CH3–CH–CH3), 1.74 (s, 3 H, CH3), 1.09 (d, J = 6.6 Hz, 6 H, CH3–CH–CH3). 13C{1H}-NMR
(101 MHz, CDCl3) δ 133.66 (1 C, m’-Ar quaternary (m-BrPh)), 133.26 (4 C, Ar quaternary
(PPh2)), 132.04 (8 C, Ar CH (PPh2)), 130.09 (1 C, Ar quaternary (m-BrPh)), 129.81 (1 C, m-Ar
CH (m-BrPh)), 129.57 (8 C, Ar CH (PPh2)), 128.02 (4 C, Ar CH (PPh2)), 127.61 (1 C, o’-Ar CH
(m-BrPh)), 124.81 (1 C, o-Ar CH (m-BrPh)), 122.31 (1 C, p-Ar CH (m-BrPh)), 110.18 (1 C, cym
quaternary), 109.26 (1 C, cym quaternary), 95.47 (2 C, cym), 92.17 (2 C, cym), 31.62 (1 C,
CH–(CH3)2), 22.64 (2 C, CH3–CH), 18.35 (1 C, CH3). 31P NMR (162 MHz, CDCl3) δ 81.21.
UV-vis: maximum absorbance at 257 nm. IR: 3053 cm−1 (C-H sp2 stretching), 2968 cm−1
(C–H sp3 stretching), 1475–1435 cm−1 (two bands C=C aromatic stretching), 1092 cm−1
(C–N stretching), 1050 cm−1 (C–P stretching), 700 cm−1 (Ru–Cl stretching). Elemental
analysis calcd (%) for C40H38BBrClF4NP2Ru: C, 53.51; H, 4.27; N, 1.56; found: C, 54.19; H,
4.59; N, 1.34. MS (ESI) m/z for [C40H38BrClNP2Ru+]: 810.04 (100%).
[RuCl(p-cym)({Ph2P}2N{C6H4Cl})][BF4] (Ru8). Yield: 51.09 mg, 0.066 mmol, 88%. 1H
NMR (400 MHz, CDCl3) δ 7.66 (d, J = 29.2 Hz, 8 H, o-Ar (PPh2)), 7.49 (t, J = 8.1, 8 H, m-Ar
(PPh2)), 7.39 (t, J = 6.8 Hz, 4 H, p-Ar (PPh2)), 6.93 (d, J = 8.6 Hz, 2 H, o-Ar (p-ClPh)), 6.45
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(d, J = 8.6 Hz, 2 H, m-Ar (p-ClPh)), 6.12 (d, 2 H, cym), 5.90 (d, 2 H, cym, 2.59–2.49 (m, 1 H,
CH3–CH–CH3), 1.75 (s, 3 H, CH3), 1.09 (d, J = 5.7 Hz, 6 H, CH3–CH–CH3). 13C{1H}-NMR
(101 MHz, CDCl3) δ 138.13 (1 C, p-Ar quaternary (p-ClPh)), 133.53 (1 C, Ar quaternary
(p-ClPh)), 133.40 (8 C, o-Ar CH (PPh2)), 133.17 (8 C, m-Ar CH (PPh2)), 132.01 (4 C, Ar
quaternary (PPh2)), 129.18 (2 C, Ar CH (p-ClPh)), 128.10 (2 C, Ar CH (p-ClPh)), 127.98
(4 C, p-Ar CH (PPh2)), 120.44 (1 C, cym quaternary), 109.75 (1 C, cym quaternary), 95.20
(2 C, cym), 92.12 (2 C, cym), 31.58 (1 C, CH–(CH3)2), 22.60 (2 C, CH3–CH), 18.23 (1 C,
CH3). 31P NMR (162 MHz, CDCl3) δ 80.65. UV-vis: maximum absorbance at 272 nm. IR:
3065 cm−1 (C–H sp2 stretching), 2969 cm−1 (C–H sp3 stretching), 1474–1434 cm−1 (two
bands C=C aromatic stretching), 1094 cm−1 (C–N stretching), 1051 cm−1 (C–P stretching),
890 cm−1 (C–Cl stretching), 696 cm−1 (Ru–Cl stretching). Elemental analysis calcd (%) for
C40H38BCl2F4NP2Ru: C, 56.29; H, 4.49; N, 1.64; found: C, 56.45; H, 4.26; N, 1.98. MS (ESI)
m/z for [C40H38Cl2NP2Ru+]: 766.09 (100%).
[RuCl(p-cym)({Ph2P}2N{C9H6N})][BF4] (Ru9). Yield: 53.20 mg, 0.068 mmol, 90%. 1H
NMR (400 MHz, CDCl3) δ 7.76–7.32 (m, 24 H, Ar (PPh2) and Ar CH3, CH8, CH9 and
CH10 (quinoline)), 7.03–6.98 (m, 1 H, Ar CH2 (quinoline)), 6.76 (d, J = 1.5 Hz, 1 H, Ar CH6
(quinoline)), 6.12 (d, J = 6.2 Hz, 2 H, cym), 5.90 (d, J = 6.5 Hz, 2 H, cym), 2.61–2.52 (m, 1 H,
CH3–CH–CH3), 1.76 (s, 3 H, CH3), 1.12 (d, J = 6.9 Hz, 6 H, CH3–CH–CH3). 13C{1H}-NMR
(101 MHz, CDCl3) δ 133.51 (1 C, C8 (quinoline)), 133.36 (8 C, o-Ar CH (PPh2)), 133.10 (1
C, C10 (quinoline)), 132.00 (8 C, m-Ar CH (PPh2)), 130.01 (1 C, C3 (quinoline)), 128.18
(1 C, C2 (quinoline)), 127.98 (4 C, p-Ar CH (PPh2)), 125.00 (1 C, C6 (quinoline)), 122.00
(1 C, C9 (quinoline)), 95.07 (2 C, cym), 92.19 (2 C, cym), 31.55 (1 C, CH–(CH3)2), 22.58
(2 C, CH3–CH), 18.20 (1 C, CH3). Quaternary carbons were not found. 31P NMR (162
MHz, CDCl3) δ 80.87. UV-vis: maximum absorbance at 257 nm. IR: 3057 cm−1 (C-H sp2
stretching), 2954 cm−1 (C-H sp3 stretching), 1498–1480 cm−1 (two bands C=C aromatic
stretching), 1093 cm−1 (C–N stretching), 1046 cm−1 (C–P stretching), 693 cm−1 (Ru–Cl
stretching). Elemental analysis calcd (%) for C43H40BClF4N2P2Ru: C, 59.36; H, 4.63; N, 3.22;
found: C, 59.39; H, 4.66; N, 3.00. MS (ESI) m/z for [C43H40ClN2P2Ru+]: 783.14 (100%).
[RuCl(p-cym)({Ph2P}2N{C12H9N2})][BF4] (Ru10). Yield: 57.18 mg, 0.068 mmol, 91%.
1H NMR (400 MHz, CDCl3) δ 8.84–8.30 (m, J = 35.6, 14.9 Hz, 27 H, Ar (PPh2) and Ar
CH3, CH5, CH10, CH11, CH12, CH13 and CH14 (azobencene)), 7.71 (d, J = 8.0 Hz, 2 H,
Ar CH2 and CH6 (azobencene)), 7.08 (s, 2 H, cym), 6.88 (s, 2 H, cym), 3.65–3.45 (m, 1 H,
CH–(CH3)2), 2.69 (s, 3 H, CH3), 2.13 (d, J = 6.8 Hz, 6 H, CH3–CH–CH3). 13C{1H}-NMR
(101 MHz, CDCl3) δ 147.44 (1 C, C9 (quaternary azobencene)), 134.38 (1 C, C1 (quaternary
azobencene)), 133.89 (1 C, Ar quaternary (PPh2)), 132.76 (8 C, Ar CH (PPh2)), 132.20 (1 C, C4
(quaternary azobencene)), 130.96 (8 C, Ar CH (PPh2)), 129.94 (5 C, p-Ar CH (PPh2) and C12
(azobencene)), 128.91 (2 C, C3 and C5 (azobencene)), 126.22 (2 C, C11 and C13 (azobencene)),
124.18 (2 C, C10 and C14 (azobencene)), 123.60 (2 C, C2 and C6 (azobencene)), 120.87 (1 C,
cym quaternary), 109.99 (1 C, cym quaternary), 96.12 (2 C, cym), 93.32 (2 C, cym), 32.28 (1
C, CH–(CH3)2), 23.31 (2 C, CH3–CH), 18.84 (1 C, CH3). 31P NMR (162 MHz, CDCl3) δ 80.39.
UV-vis: maximum absorbance at 348 nm. IR: 3065 cm−1 (C–H sp2 stretching), 2944 cm−1 (C–
H sp3 stretching), 1493 cm−1 (N=N stretching), 1482–1435 cm−1 (two bands C=C aromatic
stretching), 1093 cm−1 (C–N stretching), 1042 cm−1 (C–P stretching), 690 cm−1 (Ru–Cl
stretching). Elemental analysis calcd (%) for C46H43BClF4N3P2Ru: C, 59.85; H, 4.70; N, 4.55;
found: C, 60.12; H, 4.53; N, 4.42. MS (ESI) m/z for [C46H43ClN3P2Ru+]: 836.17 (100%).
2.4. X-ray Crystallography
Prismatic crystal for Ru3 was mounted on a glass fiber and used for data collection
on a Bruker D8 Venture with a Photon detector equipped with graphite monochromated
MoKα radiation (λ = 0.71073 Å) (Bruker Apex2, Bruker AXS Inc., Madison, WI, USA,
2004). The data reduction was performed with the APEX2 software and corrected for
absorption using SADABS [38]. Crystal structures were solved by direct methods using the
SIR97 program [39] and refined by full-matrix least-squares on F2 including all reflections
using anisotropic displacement parameters by means of the WINGX crystallographic
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package [40,41]. Generally, anisotropic temperature factors were assigned to all atoms
except for C2 and hydrogen atoms, which are riding their parent atoms with an isotropic
temperature factor arbitrarily chosen as 1.2 times that of the respective parent. Several
crystals of Ru3 were measured and the structure was solved from the best data we were
able to collect, due to the fact that the crystals diffracted very little. Final R(F), wR(F2),
and goodness of fit agreement factors, details on the data collection and analysis can be
found in Table S1. CCDC 2,076,579 contain the supplementary crystallographic data for
Ru3. These data can be obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif, accessed on 11 April 2021.
2.5. HSA Binding Studies by Steady-State Fluorescence Spectroscopy
Three milliliters of protein solution (5 µM) was titrated by successive addition of a
metallodrug stock solution. The excitation wavelength was 283 nm HSA, whereas the
emission fluorescence intensities were collected at 372 nm. The excitation and emission slits
were fixed at 5 nm. The step and dwell time was 0.1 s. For the inner filter effect fluorescence
was corrected through:
Fcorr = Fobs 10
(Aexc+Aem)
2
where Fcorr and Fobs are the corrected and observed fluorescence intensities, and Aexc and
Aem are the absorbances of the system at excitation and emission wavelengths. Temperature
was controlled at 300 K by a temperature-controlled cuvette holder, TC 125 (Quantum
Northwest), and the experiment was repeated three times.
The Stern–Volmer equation was then used to evaluate the quenching constant KSV of
the studied drug–protein systems:
F0
F
= 1 + KSV [Q]
where F0 and F are the emission intensities in the absence and the presence of the quencher,
respectively, [Q] is the concentration of the quencher (metallodrug), and KSV is the Stern–
Volmer constant [42].
For static quenching, the relationship between fluorescence intensity and the quencher






= log Ka + n log[Q]
where F0 corresponds to the fluorescence intensity of the protein in absence of quencher, n
and Ka are the number of binding sites and binding constant, respectively [43,44].
2.6. Biological Assays
The compounds were dissolved in dimethyl sulfoxide (DMSO) before performing each
experiment. The maximal concentration used was 50 µM, due to limited water solubility;
cisplatin was tested up to 100 µM [45]. The same volume of solvent was added to control
conditions and did not exceed 0.25% v/v.
Cell culture studies. The cell lines T47D, MCF7, BT474, SKBR3, BT549, HS578T, OV-
CAR8, and SKOV3 and the immortalized non-transformed keratinocyte cell line HACAT
was kindly provided by Drs. J. Losada and A. Balmain or acquired in ATCC. All lines
were grown in DMEM containing 10% fetal bovine serum (FBS) and were supplemented
with 100 U/mL penicillin, 5 mM L-glutamine, 100 µg/mL streptomycin at 37 ◦C and 5%
CO2 (Sigma-Aldrich, St. Louis, MO, USA). Carboplatin and cisplatin were purchased from
Accord Healthcare (the United Kingdom. MA).
MTT metabolization assays. For viability assessment, cell proliferation was assayed
by MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5 diphenyltetrazolium bromide) (Sigma Aldrich).
Cell lines were plated at 10,000 cells per well in 48-multiwell plates. 24 h later, the cells
were treated at correspondent doses of the drugs for 72 h. After that, the medium was
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aspirated and phenol red-free DMEM with MTT 0.5 mg/mL was added for 60 min in
growth conditions. The medium was removed and MTT crystals were solubilized with
0.5 mL of dimethylsulfoxide (DMSO) (Sigma-Aldrich) and evaluated at an absorbance of
555 nm in a multiwell plate reader.
Cell cycle and apoptosis assay. For cell cycle analyses, cell lines were plated at 100,000
cells per well in 6-multiwell plates. 24 h later, wells were treated with an IC50 dose of Ru3 for
24 h. In order to fix the cells, the cells were incubated for 15 min in 70% ethanol. After that,
pellets were washed in 2% BSA in PBS and were stained with Propidium iodide/RNAse
staining solution for 1 h at 4 ◦C in dark conditions (Immunostep S.L., Salamanca, Spain).
For apoptosis analysis, the same number of cells were treated for 48 h. Then, adherent
and floating cells were washed with PBS and incubated in Annexin V binding buffer
(Immunostep S.L.,) for 1 h in the dark with Annexin V and PI staining solution (Immunostep
S.L). Percentage of dead cells was determined considering early apoptotic (Annexin V-
positive, PI-negative), late apoptotic (Annexin V-positive and PI-positive), and residual
necrotic (Annexin V-negative, PI-positive) cells which were included as dead cells in the
analysis.
Flow cytometry assays were evaluated in a FACSCanto II flow cytometer (BD Bio-
sciences).
In vivo studies. For in vivo toxicity analysis, 12 female BALB/c nu/nu mice of 5 weeks
old were treated and weighted twice a week intraperitoneally with Ru3 or cDDP at a
fixed dose of 5mg/kg for up to four treatments. Mice were humanely sacrificed by CO2
inhalation in an appropriated chamber. This study was performed under the supervision
of the Ethics Committee and veterinary staff of Complejo Hospitalario Universitario de
Albacete. Mice were monitored and managed at the animal facility following local legal
guidelines.
2.7. Statistical Analysis
The in vitro experiments data are the average of three independent experiments
performed in triplicate, with error bars showing the standard deviation of the triplicates.
To determine significant statistical differences, equal variances Tukey’s test was used with
ANOVA, respectively, and to compare the media of experimental groups, Student’s t-test
was used. The values for the statistical analyses are: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.
3. Results
3.1. Synthesis and Characterization of Precursor Ligands and Ruthenium Compounds
At the outset, a new family of bis-phoshino-amines (PNP) ligands was synthetized.
The new PNP ligands were obtained to expand the structure space previously covered
and with the aim to generate new ruthenium therapeutic agents [36]. The PNP ligands
(L1–L10) were directly obtained by condensing chlorophosphine with the corresponding
amine in the presence of Et3N (Figure 2). Due to the abundance of commercial amines and
phosphines, this methodology is very versatile to expand ligand sets for different purposes.
To optimize the synthetic protocol, the reaction was monitored by 31P-NMR. The ligands
L1–L10 were obtained in very good yields upon extraction with toluene. Even though PNP
ligands are wide-angle bidentade ligands, mononuclear ruthenium compounds Ru1–Ru10
were obtained after exposing the corresponding ligand to [RuCl2(p-cymene)]2 in MeOH
(Figure 2). Within a 30 min reaction time, an orange solution was observed and found to
contain the mononuclear ruthenium derivative at a very good yield. Ru0 was obtained
following a procedure previously reported [36].
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chelate angle of 68.42(13)°. The Ru−centroid distance for the Ru3 complex has a value of 
1.770 Å  (Figure S7) and is standard compared to similar complexes [36]. The bond distance 
and angle values are comparable to those reported in the literature for ruthenium analogs 
[50]. 
Figure 2. Synthesis of precursor ligands L1–L10 and ruthenium compounds Ru1–Ru10.
The characterization of L1–L10 and Ru1–Ru10 were carried out by analytical methods,
infrared (IR), ultraviolet-visible (UV-Vis), and nuclear magnetic resonance (NMR) spec-
troscopy. Structural elucidation is depicted in the experimental section and illustrated as
representative examples of ligands and compounds in Figures S1–S5 in the Supporting
Information. In the IR spectrum of L1–L10 (solid state), the amine group manifested itself
with a broad band around 1020–1250 cm−1, while a strong absorption around 1090 cm−1
was attributed to the stretching vibration of the P–C moiety. The presence of two signals
at 5.7–7.1 ppm and at 90–120 ppm in the 1H and 13C{1H} NMR spectra of the ruthenium
complexes, respectively, confirmed the presence of the p-cymene ligand in the coordination
sphere. As expected, upon coordination to ruthenium, the peaks corresponding to the
phenyl rings of the PPh2 moiety shifted downfield, as noted in the 1H NMR spectrum of
complexes Ru1–Ru10. Explicitly, the characteristic signals for L1–L10 in the complexes
were downfield-shifted in all cases with regard to those of the free ligands. Moreover, the
NMR patterns of the arene resonances supported the asymmetric nature of the resulting
complexes. Indeed, the expected ABCD spin system for the p-cymene resonances was
observed. The IR spectra of Ru1–Ru10 exhibited a broad band around 300 cm−1 for the
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Ru–Cl [46,47], while a strong absorption in the range 1030–1050 cm−1 was attributed to
the stretching vibration of the P–C moiety. The UV-Vis absorption spectra of L1–L10 and
Ru1–Ru10 were recorded in DMSO solutions (10−5 M) at 25 ◦C. L1–L9 presented broad
absorption bands centered at 278–290 nm, while L10 presented intense and well-defined
characteristic bands of quinoline moieties at 358 nm. The absorption spectra of the Ru1–
Ru10 compounds featured a very intense band attributed to π−π* electronic transitions
corresponding to the Ru-(p-cymene) moiety (λ = 250–304 nm). A weak band is attributable
to metal to ligand charge transfer transitions (MLCT) from Ru d orbitals to the π* orbitals
of the ligands (304–364 nm), and a shoulder assigned to d−d transitions (364–574 nm) [46].
Single crystals suitable for X-ray diffraction were obtained by slow evaporation of
solutions of Ru3 in CH2Cl2. Selected bond lengths and angles with estimated standard
deviations are compiled in Table S1 and crystallographic refinement parameters are given
in Table S2 in the Supporting Information. Figure 3 shows the ORTEP view of Ru3 as a
representative complex of the series. The structure shows the characteristic “three-legged
piano-stool” conformation around the Ru center with a η6-coodinated p-cymene ring [48,49].
Its solid-state structure revealed a distorted tetrahedral geometry with a P-Ru-P chelate
angle of 68.42(13)◦. The Ru−centroid distance for the Ru3 complex has a value of 1.770 Å
(Figure S7) and is standard compared to similar complexes [36]. The bond distance and
angle values are comparable to those reported in the literature for ruthenium analogs [50].




Figure 3. MERCURY plot for the structure of complex Ru3. Thermal ellipsoids are given at the 30% 
probability level. Hydrogen atoms have been omitted for clarity. Selected bond distances (Å ), Ru1–
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after two weeks, with the orange/yellow solutions progressively turning to green and af-
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nium compounds relative to the free ligands could be attributable to the blocking of the 
hydrogen-bonding acceptor atoms of the ligands after coordination. Regarding the PNP 
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exceed 0.25% v/v of DMSO. Therefore, the stability of the ruthenium compounds in 
DMSO-d6 and DMSO-d6:D2O was carried out by NMR monitoring. The set of signals be-
longing to the starting ruthenium complex did not persist throughout the stability exper-
iments carried out in DMSO-d6 (25 °C). Partial release in different extents of the p-cymene 
ligand from Ru1–Ru10 was observed due to the disruptive effect of DMSO (see Table S3 
and Figure S6 as a representative example in the Supporting Information). However, this 
progressive dissociation is dismissed in the presence of water (Figure S7). The molar ratio 
between them remained constant in spectra recorded after one week in all the samples. In 
addition, the respective single set of resonances for the p-cymene ligand in the ruthenium 
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Figure 3. MERCURY plot for the structure of complex Ru3. Thermal ellipsoids are given at the
30% probability level. Hydrogen atoms have been omitted for clarity. Selected bond distances (Å),
Ru1–Cl1: 2.383(3) Å, Ru1–P1: 2.343(3) Å, Ru1–P2: 2.296(4) Å, N –P : 1.717( 1) Å, N1–P2: 1.703(11) Å.
3.2. Stability of the Ruthenium Complexes in Solution
The ligands L1–L10 were not soluble in water. Ru1–Ru10 were air stable and soluble
in chlorinated solvents, but not indefinitely stable upon air contact. According to NMR
experiments, and as a representative example, Ru3 completely degraded in chloroform
after two weeks, with the orange/yellow solutions progressively turning to green and
affording a complicated mixture of species. Qualitative tests determined that Ru4–Ru8
are slightly soluble in water and very soluble in other polar solvents such as methanol
and ethanol. Ru9–Ru10 were sparingly soluble in water, but very soluble in some organic
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solvents such as dichloromethane and dimethyl sulfoxide. The enhanced solubility of
ruthenium compounds relative to the free ligands could be attributable to the blocking of
the hydrogen-bonding acceptor atoms of the ligands after coordination. Regarding the PNP
ligand influence, the non-aromatic derivatives gave better solubilities than the aromatic
analogs because of the lower hydrophobicity. In any event, Ru1–Ru10 were soluble enough
to enable biological studies in aqueous media and circumvent hypothetical administration
problems.
As it happens to many metallodrugs, the ruthenium compounds needed to be dis-
solved in a mixture of H2O:DMSO to perform biological assays which in any case did
not exceed 0.25% v/v of DMSO. Therefore, the stability of the ruthenium compounds in
DMSO-d6 and DMSO-d6:D2O was carried out by NMR monitoring. The set of signals
belonging to the starting ruthenium complex did not persist throughout the stability exper-
iments carried out in DMSO-d6 (25 ◦C). Partial release in different extents of the p-cymene
ligand from Ru1–Ru10 was observed due to the disruptive effect of DMSO (see Table S3
and Figure S6 as a representative example in the Supporting Information). However, this
progressive dissociation is dismissed in the presence of water (Figure S7). The molar ratio
between them remained constant in spectra recorded after one week in all the samples. In
addition, the respective single set of resonances for the p-cymene ligand in the ruthenium
compounds were not modified upon the addition of 0.15 mM NaCl. The existence of only
one pattern for the ruthenium derivatives suggested ruling out fast chloride dissociation
from Ru1–Ru10, analogously to that found for RAPTA-C [51]. The mechanism of action of
RAPTA-C and its derivatives remains to be fully understood [52]. Although it is assumed
that DNA is the target for metallodrugs, evidence suggests that, for certain compounds,
proteins are likely involved in the therapeutic effect. It is well known that noncationic
complexes underwent aquation to a notable extent, depending on the counterion and the
chemical structure of the auxiliary ligand [53]. It is expected for Ru0–Ru10 the formation
of the more reactive aqua derivatives from their respective chloride precursors as the
activation step for subsequent interaction with the biological targets.
3.3. Antiproliferative Efficacy of New Synthetized Ruthenium Compounds Compared to Ru0 and
Platins
In a previous study, we reported Ru0 as the lead PNP-Ru compound by preliminary
biochemical and biological studies in different breast cancer subtypes [37]. The results
showed that complex Ru0 is much more effective in promoting in vitro cytotoxic effect on
HER2+ and RH+/HER2− breast cancer cell lines than the reference metallodrugs cisplatin,
carboplatin, or RAPTA–C [35]. Therefore, a pharmacologic screening using Ru1–Ru10
were performed in a panel of representative tumor cell lines of each subtype: luminal
(RH+/HER2−:T47D and MCF7) and HER2+ (BT474 and SKBR3) (Figure 4A). As can be
seen in Figure 4B,C, most ruthenium compounds showed better antiproliferative effects
than platinum agents used as controls in all the cancer cell lines evaluated. Ru2 and Ru3
showed the highest cytotoxic activity, being Ru3 the most active compound of all analyzed
(see IC50 values for T47D, MCF7, BT474, and SKBR3 cells of the most active ruthenium
compounds Ru0, Ru2, and Ru3 in Table 1). Ligands L1–L10 did not show significant
cytotoxicity with IC50 > 1000 (see Table S5 in the Supporting Information). Importantly,
Ru3 displayed high cytotoxicity with IC50 values lower than 1 µM, and was significantly
more cytotoxic than cisplatin and carboplatin in the cancer cell lines studied. Notably,
Ru3 was found to be highly cytotoxic in both HER2+ and luminal breast cancer cell lines,
suggesting a mode of action independent of the receptor status of the cells. The IC50
values observed for Ru3 were in the range for the most cytotoxic ruthenium complexes
reported to date [35,54]. Ru3 reports very low IC50 values, confirming its high potential
for breast cancer treatment (see IC50 values of Ru3 for all cell lines in Table 1). Otherwise,
those ruthenium compounds with aromatic rings in the PNP moiety (Ru4–Ru10) did not
reduce the cell viability by more than 50% at the concentration tested (Figure 4 and data
not shown). These results clearly indicate that the substitution in the PNP moiety can lead
to a significant increase in the cytotoxicity of the resulting complexes.
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nium compounds by exploring cell viability in BT474, SKBR3, T47D, and MCF7 breast cancer cell 
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three independent experiments performed in triplicate. To determine significant statistical differ-
ences, Student’s t-test was used. The values for the statistical analyses are: * p ≤ 0.05; ** p ≤ 0.01. 
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compounds to penetrate biological membranes, which in turn is mainly dependent on 
lipophilicity factors [53]. In this context, calculated logarithmic octanol/water partition co-
efficients (clogP) for Ru1–Ru10 were obtained using the software Molinsipiration. The var-
iability of the substitution in the PNP moiety may explain the observed lipophilicity pat-
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A general trend in which the cytotoxicity could correlate with lipophilicity was not ob-
served for these derivatives. In an effort to find a correlation between activity and affinity 
to proteins, the affinity to HSA of the most active compound of the series, Ru3, one of the 
less active, Ru8, and Ru0 for comparison were obtained by UV-Vis absorption spectros-
copy studies (see Table S4 in the Supporting Information). Unfortunately, a significant 
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3.4. Ru3 Exerts a G2/M Arrest in Breast Cancer Cell Lines 
To further explore the effect of Ru3 on cell viability, cell cycle analysis after a 24 h 
incubation period with Ru3-IC50 was performed (Figure 5) (see representative FACS plots 
for cell cycle and apoptosis in Figure S9 in the Supporting Information). Due to the prom-
ising cytotoxicity results in luminal and HER2+ cell lines, we expanded our research to 
the three breast cancer subgroups, including the basal-like subtype. As a result, six cell 
lines (BT474 and SKBR3 as HER2+, T47D and MCF7 as luminal and HS578T, and BT549 
as basal-like) were treated with either the vehicle or Ru3 for 24 h and stained with propid-
ium iodide/RNase solution. As shown in Figure 5, Ru3 blocked cell cycle progression at 
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deviation (SD) of three independent experiments performed in triplicate. To determine significant statistical differences,
Student’s t-test was used. The values for the statistical analyses are: * p ≤ 0.05; ** p ≤ 0.01.




HACAT - - 350
MCF7 300 45 15
T47D 450 60 10
HS578T - - 250
BT549 - - 45
SKBR3 700 80 60
BT474 800 180 120
OVCAR8 - - 300
SKOV3 - - 170
M ny factors could be involved in the cytotoxicity of the new ruthenium derivatives
such as physical and chemical properties, target affinity, or even plausible interaction with
other biomacromolecules. The relatively high activity exhibited by Ru3 c uld be somehow
related to the stability of the ruthenium complexes in biological media. Table S3 in the
supporting information showed the high stability of these compounds in water which rule
out any potential relationship between stability and cytotoxicity. On the other hand, the
variability in the pharmacological profiles observed might depend on the ability of these
compounds to penetrate biological membranes, which in turn is mainly dependent on
lipophilicity factors [53]. In this context, calculated logarithmic octanol/water partition
coefficients (clogP) for Ru1–Ru10 were obtained using the software Molinsipiration. The
variability of the substitution in the PNP moiety may explain the observed lipophilicity
pattern. Figure S8 in the supporting information depicts the logP versus %MTTs trans-
formed. A general trend in which the cytotoxicity could correlate with lipophilicity was not
observed for these derivatives. In an effort to find a correlation between activity and affinity
to proteins, the affinity to HSA of the most active compound of the series, Ru3, one of the
less active, Ru8, and Ru0 for comparison were obtained by UV-Vis absorption spectroscopy
studies (see Table S4 in the Supporting Information). Unfortunately, a significant difference
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in the Ka values was not observed between species which did not facilitate the discovery of
any structure–activity relationship.
3.4. Ru3 Exerts a G2/M Arrest in Breast Cancer Cell Lines
To further explore the effect of Ru3 on cell viability, cell cycle analysis after a 24 h
incubation period with Ru3-IC50 was performed (Figure 5) (see representative FACS plots
for cell cycle and apoptosis in Figure S9 in the Supporting Information). Due to the
promising cytotoxicity results in luminal and HER2+ cell lines, we expanded our research
to the three breast cancer subgroups, including the basal-like subtype. As a result, six cell
lines (BT474 and SKBR3 as HER2+, T47D and MCF7 as luminal and HS578T, and BT549 as
basal-like) were treated with either the vehicle or Ru3 for 24 h and stained with propidium
iodide/RNase solution. As shown in Figure 5, Ru3 blocked cell cycle progression at the
G0/G1 phases in all of the cell lines evaluated except for the HER2-positive subgroup
(SKBR3 and BT474).
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3.5. Ru3 Exerts Apoptotic-Based Cell Death in TNBC
On the basis of the cytotoxic results of Ru3 in breast cancer cell lines, the mechanism
of cell death induction was evaluated. We analyzed Ru3 ability to induce apoptosis by
flow cytometry as previously described [37,53,55–57]. The experiments were performed
using an incubation time of 48 h, and Ru3 concentrations corresponding to their respective
IC50 value. Treatment with Ru3 was able to significantly increase apoptosis in all the cell
lines analyzed, (Figure 6), suggesting that the lead compound clearly induces cell death by
apoptosis in a wide range of breast cancer cell lines.




Figure 6. Evaluation of cell death mechanism exerted by Ru3 in several breast cancer cell line mod-
els. Cell death was evaluated in HER2+ (A), basal (B), and luminal (C) cell lines by Annexin V/pro-
pidium iodide staining and cytometer evaluation after 48 h using the IC50 Ru3 dose treatment spe-
cific each cell line. Data are the average +/− standard deviation (SD) of three independent experi-
ments performed in triplicate. To determine significant statistical differences between living cells 
groups, Student’s t-test was used. The values for the statistical analyses are: *, p ≤ 0.05; **, p ≤ 0.01; 
***, p ≤ 0.001. 
3.6. Ru3 Is Less Toxic than Cisplatin Using In Vitro and in In Vivo Studies 
We next evaluated the in vitro effect of Ru3 on the viability of non-tumoral cells. To 
this end, we used the non-transformed but immortalized keratinocytes cell line HACAT. 
Interestingly, Ru3, the most potent compound of the series, did not display significant 
toxicity in non-tumoral cells, showing IC50 values which doubled one of the transformed 
cell lines (Figure 7A and Table 1). The in vivo toxicity of Ru3 and cisplatin was evaluated 
by measuring the animal body weight and their behavior. Treatment with Ru3 and cispla-
tin was performed using 5 mg/kg intraperitoneal (IP) doses for seven consecutive days. 
As displayed in Figure 7B, Ru3 did not induce significant weight loss compared with cis-
platin where a 30% weight reduction was observed. No lethality was reported after seven 
days of treatment with both compounds. This data suggests that a repeated dose of Ru3 
is much better tolerated than cisplatin. On the other hand, in the HACAT cell line, the 
effects over cell cycle distribution were almost undetectable after 24 h at a 200 nM (Figure 
7C), a treatment dose that would cause high toxicity on breast cancer cell lines. Moreover, 
the effect of that dose over cell death was weaker than the one caused to breast cancer cell 
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by measuring the animal body weight and their behavior. Treatment with Ru3 and cisplatin
was performed using 5 mg/kg intraperitoneal (IP) doses for seven consecutive days. As
displayed in Figure 7B, Ru3 did not induce significant weight loss compared with cisplatin
where a 30% weight reduction was observed. No lethality was reported after seven days
of treatment with both compounds. This data suggests that a repeated dose of Ru3 is
much better tolerated than cisplatin. On the other hand, in the HACAT cell line, the effects
over cell cycle distribution were almost undetectable after 24 h at a 200 nM (Figure 7C), a
treatment dose that would cause high toxicity on breast cancer cell lines. Moreover, the
effect of that dose over cell death was weaker than the one caused to breast cancer cell lines,
despite being statistically significant (Figure 7D).




Figure 7. Ru3 displays less toxicity in non-transformed cells. (A) IC50 comparison, measured by MTT 
metabolization, between breast cancer cell lines and HACAT, showing that the IC50 of the non-trans-
formed cell line at least doubles the value of the transformed cell lines. (B) Ru3 shows lower toxicity 
in vivo than platin compounds. Toxicity was evaluated after 7 days of IP treatment with 5 mg kg−1 
twice a week. Ru3 (N = 6) exerted significantly less toxicity than cDDP (N = 6) at the 5 mg kg−1 with 
a treatment schedule of two administrations a week. (C) The effect of Ru3 in HACAT cell lines in 
terms of cell cycle arrest, demonstrating no modifications in any cell cycle phase. (D) Cell death was 
evaluated, and weaker effects were observed when compared to breast cancer cell lines at the dose 
of 200 nM. Data are the average +/- standard deviation (SD) of three independent experiments per-
formed in triplicate. To determine significant statistical differences between the averages of treat-
ment groups, G0/G1 or living cells groups respectively, Student’s t-test was used. The values for the 
statistical analyses are: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
3.7. Ru3 Is Also a Therapeutic Alternative in Ovarian Cancer 
TNBC share many biological similarities with ovarian cancer including that both tu-
mors display a high grade of antitumor sensitivity to platinum agents. In this context, we 
aimed to evaluate the activity of this agent in two well-characterized ovarian cancer cell 
lines, SKOV3 and OVCAR8, in comparison to cisplatin (cDDP) (Figure 8A,B). To detect 
differences, we used doses of cisplatin below their IC50 (Figure 8C). As can be seen in Fig-
ure 8, cisplatin showed modest activity and the action of Ru3 was much potent at the low 
doses used. 
Figure 7. Ru3 displays less toxicity in non-transformed cells. (A) IC50 comparison, measured by MTT metabolization,
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Cisplatin. In our case, both characteristics are included in the family of new agents
described in this report.
Our previous studies allow us to validate PNP-Ru compounds as anticancer drugs
for breast cancer therapy establishing a proof of concept for further optimization and
characterization of novel agents. In this case, further rational modifications of the molecular
structure were required to improve the pharmacological profile of these derivatives. A
set of novel PNP ligands was designed to prepare an ample series of ruthenium(II) arene
complexes, with the aim of fine-tuning the cytotoxic properties of these types of promising
anticancer drugs. Our results suggest that slight modifications in the molecular structure
of the PNP-Ru compounds is decisive for tuning its antitumoral activity.
In our work, we position Ru3 as the lead compound of the series. Three reasons justify
this approach: (1) Ru3 is the most potent antitumoral compound of the series, able to induce
Pharmaceutics 2021, 13, 1559 19 of 22
cell death without affecting non-transformed cells; (2) its antitumoral action is related to
the activation of the intrinsic apoptotic pathway and displays a pharmacological profile
that is maintained in cisplatin-resistant cells; (3) it shows less acute toxicity in vitro and
in vivo than the reference metallodrug cisplatin and supporting its evaluation in different
solid tumors where DNA-damaging agents have a role.
An interesting finding was the fact that Ru3 induced a profound anti-tumoral effect in
TNBC and ovarian cancer cell lines, and that the mechanism of action was mainly mediated
by apoptotic cell death. Of note, only a slight increase in G0/G1 was detected, suggesting
that the compound is cytotoxic rather than cytostatic. The relevant induction of apoptosis is
shared by other metallodrugs such as platinum agents although our drug displayed a safer
toxicity profile with a more antitumoral activity [9]. On the other hand, when compared
with cisplatin, Ru3 was less toxic in non-transformed cells and did not induce weight loss
in animals after a maintainance dose administration. These findings, in addition to the
clear antitumoral activity in vitro of Ru3 compared with cisplatin or carboplatin, position
this compound as a future alternative for clinical development. In addition, Ru3 displayed
a significant antitumoral activity in ovarian cancer, which suggests that these agents can
cover a wide range of clinical necessities.
On the other hand, we acknowledge that the full mechanism of action of the compound
has not been evaluated in this first study. We could speculate that induction of DNA could
be one of those mechanisms, but not the principal, considering the significant induction of
cell death observed after its administration. In this context, as an apoptotic inducer agent,
combination with other agents acting on complementary molecular vulnerabilities could
be exploited, such as the combination with anti-HER2 therapies. Our previous experience
reinforces this approach.
5. Conclusions
In conclusion, the structure of Ru3 might serve as the basis for the design of more
active and less toxic antitumoral compounds and pave the way for the clinical development
of these compounds as alternatives for the treatment of tumors. The simple accessible
synthesis of this compound and its biological activity makes Ru3 a good candidate for
further evaluation in vivo as a potential chemotherapeutic agent against breast cancer.
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